AstraZeneca is driven by a diversified portfolio, robust R&D, and strong FCF, despite a current valuation that is slightly ...

According to MarketsandMarkets(TM), the Next Generation Drug Conjugates Market is projected to grow from about USD 15.75 billion in 2026 to USD 42.55 billion by 2035, at a CAGR of 11.7%. Browse 260 ...

According to MarketsandMarkets™, the Next Generation Drug Conjugates Market is projected to grow from about USD 15.75 billion ...

Two years ago, the Emerald-1 trial hit its primary endpoint, showing that a cocktail of Imfinzi, Avastin and TACE reduced the ...

Positive high-level results from the EMERALD-3 Phase III trial showed AstraZeneca's Imfinzi (durvalumab) in combination with Imjudo (tremelimumab ...

In this video, Hope S. Rugo, MD, discusses two debates during Miami Breast Cancer Conference that highlighted treatment and testing decisions in breast cancer care.According to Rugo, director of the ...

Find insight on AstraZeneca, Biogen’s deal to acquire Apellis Pharmaceuticals, and more in the latest Market Talks covering the Health Care sector.

Pfizer’s oncology revenues grew 8% in 2025, driven by drugs like Xtandi, Lorbrena, the Braftovi-Mektovi combination and ...

Zongertinib provided substantial clinical benefit for patients with advanced or metastatic HER2-mutant advanced non-small cell lung cancer, surpassing the historical standard of care efficacy for this ...

Elinzanetant reduces the severity and frequency of hot flushes and night sweats among women with breast cancer regardless of ...

Japan's Daiichi Sankyo and the United Kingdom's AstraZeneca announced on Friday that their co-developed innovative medicine, ...